Hot topics
LDL binding to the LDL receptor: Structural insights
Reports from the 21st Virtual Closed Scientific Expert Meeting of the Editorial Board Alan Remaley
read more »
AZD0780: A small molecule inhibitor of PCSK9 – Early clinical data
Reports from the 21st Virtual Closed Scientific Expert Meeting of the Editorial Board Rick Vega
read more »
Lerodalcibep, a third generation PCSK9 inhibitor: Overview of completed phase 3 programme
Reports from the 21st Virtual Closed Scientific Expert Meeting of the Editorial Board Dirk Blom
read more »
The trajectory of ASCVD: Focus on subclinical atherosclerosis
Reports from the 21st Virtual Closed Scientific Expert Meeting of the Editorial Board Borja Ibanez
read more »
Post-ACS therapeutic strategies: What has changed?
Reports from the 20th Virtual Closed Scientific Expert Meeting of the Editorial Board Matthew Budoff
read more »
CRISPR engineering of wild-type alleles versus millions of years of human evolution
Reports from the 20th Virtual Closed Scientific Expert Meeting of the Editorial Board Steven Farber
read more »
The statin intolerant patient with ASCVD: What is your therapeutic strategy?
Reports from the 20th Virtual Closed Scientific Expert Meeting of the Editorial Board Ioanna Gouni-Berthold
read more »
PCSK9 inhibition with a novel fusion protein
Reports from the 20th Virtual Closed Scientific Expert Meeting of the Editorial Board Frederick Raal
read more »
Oral PCSK9 inhibition: Clinical update
Reports from the 20th Virtual Closed Scientific Expert Meeting of the Editorial Board Christie Ballantyne
read more »
What do you do after a Statin? So many choices… what is yours?
Reports from the 19th Virtual Closed Scientific Expert Meeting of the Editorial Board Anne Goldberg
read more »
Keynote – HDL and PCSK9: Going for a ride?
Reports from the 19th Virtual Closed Scientific Expert Meeting of the Editorial Board Manuel Mayr
read more »
PCSK9 targeting: Inside versus outside?
Reports from the 19th Virtual Closed Scientific Expert Meeting of the Editorial Board Alberto Corsini
read more »
Statins and PCSK9 inhibitors in combination: Initial therapy in very high-risk patients in secondary prevention
Reports from the 18th Virtual Closed Scientific Expert Meeting of the Editorial Board Alberto Zambon
read more »
Elevated LDL-C and elevated Lp(a) with recurrent MACE: What to do, to do what?
Reports from the 18th Virtual Closed Scientific Expert Meeting of the Editorial Board Erik Stroes
read more »
Aortic valve stenosis: A key pathophysiological role for Lp(a)?
Reports from the 18th Virtual Closed Scientific Expert Meeting of the Editorial Board Benoit Arsenault
read more »
Lp(a) and plaque progression: Insights from imaging
Reports from the 18th Virtual Closed Scientific Expert Meeting of the Editorial Board Marc Dweck
read more »
LDL-C lowering with PCSK9 inhibition: Multi-modal imaging and impact on coronary plaque in ACS patients
Reports from the 18th Virtual Closed Scientific Expert Meeting of the Editorial Board Stephen Nicholls
read more »
siRNA-mediated lowering of Lp(a) by Olpasiran
Reports from the 17th Virtual Closed Scientific Expert Meeting of the Editorial Board Michael Koren
read more »
A new ASO PCSK9 inhibitor: The Etesian study
Reports from the 17th Virtual Closed Scientific Expert Meeting of the Editorial Board Alexis Hofherr
read more »
ASO-mediated reduction in Lp(a) levels: Update on Pelacarsen
Reports from the 17th Virtual Closed Scientific Expert Meeting of the Editorial Board Sotirios Tsimikas
read more »
